Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

4D Molecular Therapeutics Inc (NQ: FDMT )

7.620 -0.170 (-2.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics Inc

< Previous 1 2 3 4 5 6 7 Next >
Why Is Eye Disease-Focused 4D Molecular Therapeutics Stock Shooting Higher Today?
4D Molecular Therapeutics data in wet AMD treatment. Phase 2 PRISM trial shows promising results - 89% reduction in anti-VEGF injections, stable visual acuity. 
Via Benzinga
Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday
U.S. stocks traded lower, with the Dow Jones falling over 300 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Tumbles 150 Points; McDonald's Sales Miss Views
U.S. stocks traded lower this morning, with the Dow Jones index falling around 150 points on Monday. Following the market opening Monday, the Dow traded down 0.41% to 38,494.03 while the NASDAQ fell... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics
Via Benzinga
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning! 
Via InvestorPlace
4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
4DMT Appoints Uneek Mehra as Chief Financial and Business Officer
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT to Participate in Upcoming Investor Conferences
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data
From 4D Molecular Therapeutics, Inc.
Via GlobeNewswire
4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst
Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) with a Buy rating and  
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.